ArticleInternational journal of clinical and experimental pathology2015
Icariside II promotes osteogenic differentiation of bone marrow stromal cells in beagle canine.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Pharmacological and Therapeutic Potential of a Natural Flavonoid Icariside II in Human Complication.Current drug targets · 2025Review
- Icariside II protects from marrow adipose tissue (MAT) expansion in estrogen-deficient mice by targeting S100A16.Journal of molecular endocrinology · 2024Article
- The Role of Flavonoids in the Osteogenic Differentiation of Mesenchymal Stem Cells.Frontiers in pharmacology · 2022Review
- Tradition to Pathogenesis: A Novel Hypothesis for Elucidating the Pathogenesis of Diseases Based on the Traditional Use of Medicinal Plants.Frontiers in pharmacology · 2021Review
- Effects of icariin on the proliferation and osteogenic differentiation of human amniotic mesenchymal stem cells.Journal of orthopaedic surgery and research · 2020Article
- Effects of icariside II on brain tissue oxidative stress and Nrf2/HO-1 expression in rats with cerebral ischemia-reperfusion injury1.Acta cirurgica brasileira · 2019Article
- A Review on the Effect of Plant Extract on Mesenchymal Stem Cell Proliferation and Differentiation.Stem cells international · 2019Review
- Study of the osteogenesis effect of icariside II and icaritin on canine bone marrow mesenchymal stem cells.Journal of bone and mineral metabolism · 2018Article
- Synthesis and Biological Evaluation of Novel Alkyl Amine Substituted Icariside II Derivatives as Potential Anticancer Agents.Molecules (Basel, Switzerland) · 2018Article
- Icariside II promotes the osteogenic differentiation of canine bone marrow mesenchymal stem cells via the PI3K/AKT/mTOR/S6K1 signaling pathways.American journal of translational research · 2017Article
- The Anticancer Properties of Herba Epimedii and Its Main Bioactive Componentsicariin and Icariside II.Nutrients · 2016Review
- Comparative Pharmacokinetics Study of Icariin and Icariside II in Rats.Molecules (Basel, Switzerland) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Icariside II (ICS II) is a prenylated active flavonol from the roots of epimedium koreanum Nakai, and has many biological activities, including anti-osteoporosis, anti-hypoxia and anti-cancer activities. In this study, we aimed to study the effect of ICS II on osteogenic differentiation of bone marrow derived stromal cells (BMSCs). Cell surface markers of cultured BMSCs were analyzed by flow cytometry and identified by multi-lineage differentiation assays. BMSCs proliferation was determined by the cell counting kit-8 (CCK-8) assay for 2, 4, 6 and 8 days in a range of ICS II concentrations. The osteogenic response of BMSCs to ICS II in vitro was examined by alkaline phosphatase (ALP) activity assay and Alizarin red staining on calcium nodule formation. Results showed ICS II significantly improved ALP activity, and calcium deposition. The optimal concentration of ICS II for enhancing osteogenic differentiation of BMSCs was 10(-5). Therefore, we concluded ICS II can enhance the osteogenic differentiation of BMSCs which may be useful in clinic.
Indexed as
Identifiers
26191128PMC4503000W2433083314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.